Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Management and Treatment of Diabetic Macular Edema After Protocol T [SUPPLEMENT]

By: Rishi P. Singh, MD, moderator; Mandeep Brar, MD; Mark Dunbar, OD; John W. Kitchens, MD

This course has expired. You can still review the content but course credit is no longer available.

Supplement Credits: 1

Expiration Date: Friday, June 30, 2017
Release Date: June 2016

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Assess clinical studies involving new approaches to treat DME, with particular attention to the DRCR.net’s Protocol T
  • Differentiate existing DME intravitreal therapy options from recent primary and secondary treatments
  • Evaluate treatment options and develop criterion/criteria on when to initiate or alter therapy
  • Discuss case scenarios and apply data from recent clinical studies to better manage patients with DME

Accreditation and Designation Statement

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC, New Retina MD, Retina Today and Advanced Ocular Care. Evolve Medical Education LLC is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Evolve Medical Education LLC (Evolve) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Faculty and Disclosures

Rishi P. Singh, MD, moderator
Cole Eye Institute, Cleveland Clinic
Cleveland, Ohio

Mandeep Brar, MD
Abrazo Medical Group
Glendale, Arizona

Mark Dunbar, OD
Bascom Palmer Eye Institute
Miami, Florida

John W. Kitchens, MD
Retina Associates of Kentucky
Lexington, Kentucky

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity. The following faculty members have the following financial relationships with commercial interests:

Rishi P. Singh, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Genentech; Regeneron Pharmaceuticals; and ThromboGenics NV. Contracted Research: Alcon; Genentech; Regeneron Pharmaceuticals.

Mandeep Brar, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Janssen Pharmaceutical; and Regeneron Pharmaceuticals.

Mark Dunbar, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan; Carl Zeiss Meditec; and Regeneron Pharmaceuticals.

John W. Kitchens, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan; Genentech; Synergetics USA; and ThromboGenics NV.

Cheryl Cavanaugh, MS, Evolve; Emily Feinman, New Retina MD, Retina Today, Advanced Ocular Care; Michelle Dalton, writer; and Melanie Lawler, PhD, reviewer, have no financial relationships with commercial interests

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, New Retina MD, Retina Today, Advanced Ocular Care, or Regeneron Pharmaceuticals.

Management and Treatment of Diabetic Macular Edema after Protocol T : SUPPLEMENT

Rishi P. Singh, MD, moderator; Mandeep Brar, MD; Mark Dunbar, OD; John W. Kitchens, MD

BackNext